Thirteen serious adverse reactions per 100 thousand vaccine doses. These are the data that emerged from the eighth Aifa pharmacovigilance report on Covid vaccines between 27 December 2020 and 26 August 2021 for the four vaccines in use in the campaign.
In the period considered, explains Aifa, 91,360 reports were received out of a total of over 76.5 million doses administered (reporting rate of 119 per 100 thousand doses), of which 86.1% referred to non-serious events. such as injection site pain, fever, asthenia / fatigue, muscle aches. Serious reports correspond to 13.8%, with a rate of 13 serious events per 100 thousand doses. Regardless of the vaccine, the dose and the type of event, the reaction occurred in most cases (about 80%) on the same day of vaccination or the next day and only more rarely beyond the following 48 hours. The data concerning young people is also good. In the 12-19 age group, from V-Day of 27 December 2020 to 26 August, the National Pharmacovigilance Network received 838 reports of suspected adverse events to vaccines out of a total of 3.7 million doses, with a reporting rate of 22 per 100 thousand doses administered. “The distribution by type of adverse events is not substantially different from that observed for all other age groups” underlines the national regulatory body.
And the serum for the 5-11 age group is also on the way. “In the coming weeks we will globally present the results of our studies to the authorities and we will request the authorization of the vaccine for this age group also in Europe” explains the co-founder of the German company BioNTech, Ozlem Tureci. «We are already preparing the production», added Tureci, «the vaccine is the same, but with a lower dosage. The first children under the age of 12 could already be vaccinated in Germany from mid-October ».
If the data on the mass vaccination campaign are heartening, Aifa instead raises the alarm on the use of an antiviral drug, unsuitable to protect against the virus. This is Parvulan, containing Corynebacterium parvum and without marketing authorization in Italy, legally registered and marketed in Brazil to combat Covid. The drug, born against dermatological infections and adjuvant in the treatment of acne and effective against herpes, was prescribed as a therapy for the prevention of Covid, as an alternative to authorized vaccines. And it proved dangerous for a reason: it caused those who hired it to feel protected by Covid and not to get vaccinated. “At the moment there is no drug that replaces the vaccine – warns the pharmacologist Silvio Garattini, founder of the Mario Negri institute – except for monoclonal antibodies which, however, have a limited action over time, unlike vaccination which gives long-term coverage “.